Conclusions: The PaO2 in arterial blood is associated with post-LT mortality in HPS patients receiving MELD exceptions. We defined PaO2 cutpoints to risk stratify post-LT survival. Consideration of revising HPS exception policies to define lower limits of PaO2 for exception points may be appropriate to ensure acceptable post-LT outcomes in HPS patients. Pa02 category, mmHg Standard Pa02 Cubic

spline Pa02 < 50 50-59 60-69 <44.0 441.−54.0 54.1-61.0 61.1-69.9 1-year survival 86.9% 93.0% 87.4% 82.6% 91.4% 93.0% 84.0% 3-year survival 75.9% 86.0% 77.9% 68.6% 83.1% 86.7% 72.2% 5-year survival 69.8% 80.1% 75.6% 59.5% 77.5% 82.1% 69.2% Disclosures: Michael B. Fallon - Advisory Committees or Review Panels: Bayer/Onyx; Grant/Research Support: Ikaria Therapeutics, Gilead, ANADYS, Mochida, Eaisi, Research Triangle Institute The following

people have nothing to disclose: David S. Goldberg, Sachin Batra, Rajasekhar Tanikella, Steven M. Kawut “
“Liver SAHA HDAC transplantation (LT) is the best treatment option for patients with end-stage liver disease. Living donor LT (LDLT) has developed as an alternative to deceased donor LT (DDLT) in order find more to overcome the critical shortage of deceased organ donations, particularly in Asia. LDLT offers several advantages over DDLT. The major advantage of LDLT is the reduction in waiting time mortality. Especially among patients with hepatocellular carcinoma (HCC), LDLT can shorten the waiting time and lower the dropout rate. The Hong Kong group reported that median waiting time was significantly shorter for LDLT than for DDLT. Intention-to-treat

survival rates of HCC patients with voluntary live donors were significantly 上海皓元医药股份有限公司 higher than those of patients without voluntary live donors. In contrast, a multicenter adult-to-adult LDLT retrospective cohort study reported that LDLT recipients displayed a significantly higher rate of HCC recurrence than DDLT recipients, although LDLT recipients had shorter waiting times than DDLT recipients. The advantage of LDLT involves the more liberal criteria for HCC compared with those for DDLT. Various preoperative interventions including nutritional treatment can also be planned for both the donor and recipient in LDLT. Conversely, LDLT has marked unfavorable characteristics in terms of donor risks. Donor morbidity is not infrequent and the donor mortality rate is estimated at around 0.1–0.3%. In conclusion, living donation is not necessarily advantageous over deceased donation in LT. Taking the advantages and disadvantages of each option into consideration, LDLT and DDLT should both be used to facilitate effective LT for patients requiring transplant. Liver transplantation (LT) has become the best treatment modality for patients with end-stage liver disease. In Western countries, deceased donor LT (DDLT) has mainly been performed. In contrast, living donor LT (LDLT) has developed as an alternative to DDLT to overcome the critical shortage of deceased organ donations, particularly in Asia.